Company: SXTPW
Filing Date: 2025-09-05
Form Type: 8-K
Source: 0001213900-25-085040
Chunk: 0

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material
Definitive Agreement.

On September 3, 2025, 60 Degrees Pharmaceuticals,
Inc. (the “ Company”) entered into an At-The-Market Sales Agreement (the “ Sales Agreement”) with H. C. Wainwright
& Co., LLC (“ Wainwright”) pursuant to which the Company may, from time to time, offer and sell shares (the “ ATM
Shares”) of its common stock, par value $0.0001 per share (the “ Common Stock”), having aggregate gross sales proceeds
of up to $1,397,533 (the “ ATM Offering”), through or to Wainwright, acting as sales agent or principal, subject to the Company’s
current “baby shelf” limitations under General Instruction I. B.6. of Form S-3.

Subject to the terms and conditions of the Sales
Agreement, Wainwright will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the
ATM Shares from time to time, based upon the Company’s instructions. The Company has provided Wainwright with customary indemnification
and contribution rights in favor of the Agents, and the Wainwright will be entitled to a commission of 3.0% of the gross proceeds from
each sale of the ATM Shares pursuant to the Sales Agreement.

Sales of the ATM Shares, if any, under the Agreement
will be made by any method permitted by law deemed to be “at the market offerings” as defined in Rule 415 under the Securities
Act of 1933, as amended (the “ Securities Act”). The Company has no obligation to sell any of the ATM Shares and may at any
time suspend offers under the Sales Agreement or terminate the Sales Agreement.

This description of the Sales Agreement does not
purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is attached hereto as Exhibit 1.1 and
incorporated by reference herein.

The Company Common Stock to be sold under the
Sales Agreement, if any, will be issued and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-280796),
which was filed with the Securities and Exchange Commission (the “ SEC”) on July 12, 2024, and declared effective by the (“ SEC”)
on July 18, 2024, including the base prospectus contained therein, and a prospectus supplement dated September [_